S-[2-[4-[(1-methylbenzimidazol-5-yl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate | 940951-53-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: S-[2-[4-[(1-methylbenzimidazol-5-yl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate
• CAS: 940951-53-1
• 化学式: C₁₈H₁₇N₃O₄S₂
• 分子量: 403.483
• InChiKey: JYOAACIQZZNFCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-[4-(2-bromoacetyl)phenyl]-1-methylbenzimidazole-5-sulfonamide 、 potassium thioacetate 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 S-[2-[4-[(1-methylbenzimidazol-5-yl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate
  参考文献：
  名称：

  α-Mercaptoketone based histone deacetylase inhibitors

  摘要：

  In an effort to discover novel non-hydroxamic acid histone deacetylase (HDAC) inhibitors, a novel alpha-mercaptoketone was identified in a high-throughput screen. Lead optimization of the screening hit, led to a number of potent HDAC inhibitors. In particular, alpha-mercaptoketone 19y (KD5150) exhibited nanomolar in vitro activity and inhibition of tumor growth in vivo. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.058

文献信息

• [EN] INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS D'HISTONE DESACETYLASE POUR LE TRAITEMENT DE MALADIES
  申请人：KALYPSYS INC

  公开号：WO2007067993A1

  公开（公告）日：2007-06-14

  [EN] Disclosed herein are compounds of formula I and methods used for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine- repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
  [FR] La présente invention concerne des composés et des procédés utilisés pour traiter des états pathologiques comprenant, sans y être limités, des cancers, des maladies auto-immunes, des lésions tissulaires, des troubles du système nerveux central, des maladies neurodégénératives, la fibrose, des troubles osseux, des troubles de répétition de polyglutamine, des anémies, des thalassémies, des états inflammatoires, des troubles cardiovasculaires, et des troubles dans lesquels l'angiogenèse joue un rôle dans la pathogenèse. De plus, la présente invention concerne des procédés de modulation de l'activité de l'histone désacétylase (HDAC).
• α-Mercaptoketone based histone deacetylase inhibitors
  作者：Paul L. Wash、Timothy Z. Hoffman、Brandon M. Wiley、Céline Bonnefous、Nicholas D. Smith、Michael S. Sertic、Charles M. Lawrence、Kent T. Symons、Phan-Manh Nguyen、Kevin D. Lustig、Xin Guo、Tami Annable、Stewart A. Noble、Jeffrey H. Hager、Christian A. Hassig、James W. Malecha

  DOI：10.1016/j.bmcl.2008.10.058

  日期：2008.12

  In an effort to discover novel non-hydroxamic acid histone deacetylase (HDAC) inhibitors, a novel alpha-mercaptoketone was identified in a high-throughput screen. Lead optimization of the screening hit, led to a number of potent HDAC inhibitors. In particular, alpha-mercaptoketone 19y (KD5150) exhibited nanomolar in vitro activity and inhibition of tumor growth in vivo. (C) 2008 Elsevier Ltd. All rights reserved.